title: Serial changes of serum cytokines in Crohn's disease following treatment with adalimumab.
abstract: OBJECTIVE
  We examined serum cytokine levels in Crohn's disease (CD) patients before and after Adalimumab (ADA) treatment.
  
  
  METHODS
  A total of 24 patients with CD were enrolled (4 colonic type, 6 ileal type, 14 ileo-colonic type). Patients were divided into two groups according to disease duration. Patients were given ADA (160 mg at week 0 and 80 mg at week 2), followed by maintenance therapy (40 mg every other week). Serum levels of 17 cytokines were simultaneously determined using a Bio-Plex suspension array system before, 4 and 8 weeks after ADA treatment. Serum CRP levels were also measured before, 4 and 8 weeks after treatment.
  
  
  RESULTS
  IL-6 and MCP-1 levels were significantly decreased in all CD patients and in the ileo-colonic type 8 weeks after ADA treatment compared to before treatment (P <0.05). MCP-1 levels were significantly decreased 8 weeks after treatment compared to pre-treatment samples if disease onset occurred longer than 8 years. A significant correlation was noted between CRP and IL-6 levels.
  
  
  CONCLUSIONS
  The reduction of IL-6 and MCP-1 would be an important role for the improvement of inflammation after ADA treatment in CD which might be associated with disease types and disease duration,
authors.forename: Yukito
authors.initials: Y
authors.lastname: Abiko
authors.forename: Tomomi
authors.initials: T
authors.lastname: Mizutani
authors.forename: Toshimi
authors.initials: T
authors.lastname: Chiba
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D015331:Cohort Studies; D003424:Crohn Disease / Q000097:blood* / Q000188:drug therapy*; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D002097:C-Reactive Protein; D000068879:Adalimumab